hjc黄金城專題研討會開啟英國之旅

hjc黄金城2023年度英國研討會 (Medicilon’s 2023 Annual UK Symposium: New Approaches to Facilitate Drug Discovery) 將於當地時間4月21日舉辦。 此次活動在英國劍橋科技園巴布拉漢姆研究園區 (Babraham research campus) 進行。我們期待您的光臨！

時間| Friday, April 21st,12:00-18:00 pm

地點| Babraham Research Campus, King's Hedges Room

演講嘉賓

Shaun McNulty博士，高級科學顧問

Shaun is an experienced drug discoverer with over 30 years of experience in the biotechnology and pharmaceutical sectors. He is an experienced biotechnology executive, specialising in drug development strategy and the successful transfer of drug candidates into clinical trials. Shaun obtained his doctorate in kinase-mediated signalling from the University of York and undertook post-doctoral research on neuronal signalling pathways at the University of Cambridge. He then held positions of increasing seniority for Pfizer and GSK, managing development teams and small molecule programmes for preclinical development. He moved into the Biotechnology sector in 2006, joining Syntaxin to direct their discovery portfolio. He then moved to ImmBio, directing scientific collaborations and fundraising. Shaun has worked as a biotech executive for 9 years first as Biosceptre’s CSO, then working for Inflection and Awakn Life Sciences. He worked in the contract research sector as a Director of Biology for Charles River.

戴學東 博士 國際研發服務部執行副總裁

美國麻省理工大學有機化學博士，博士後，深耕於中樞神經係統疾病、傳染病和腫瘤疾病化學藥物的研發20餘載，對藥物發現過程中包括苗頭化合物的確定及優化，以及成功發展到高質量的臨床候選化合物有著深刻的理解和豐富的實踐經驗。戴學東博士參與主持研發的藥物有已上市藥物，如Horizant®/Regnite®；臨床藥物，如JNJ-75276617；臨床候選化合物，如Arbaclofen Placarbil，XP21279，XP23829等。

曹保紅 博士 藥理部副總裁

北京醫科大學醫學博士。曾在丹麥國家血清研究所、美國匹茲堡大學及匹茲堡兒童醫院、美國貝納羅亞研究所等從事研究工作，在Nature Cell Biology, Nature Biotechnology, Journal of Cell Biology 等國際頂級學術期刊發表論文多達24篇，所研究項目曾兩次獲得獲美國國立衛生研究院重要課題（NIH R01）資助。加入hjc黄金城之前，曹博士曾擔任藥明康德美國分公司免疫腫瘤學高級主任，MI Bioresearch（現由科文斯收購）研究運營總監，上海睿智化學研究有限公司、諾華（中國）生物醫學研究中心等的高級管理職務。超25年醫藥研發經驗，超10年團隊管理經驗，曹博士在藥物發現領域造詣深厚，尤其在腫瘤疾病模型構建和CAR-T細胞治療方麵頗有建樹，是一位醫藥研發知識淵博、成績斐然的行業領軍人物。

Marshal Ma, 歐洲業務發展副總裁

Marshal Ma has over 30 years’ experience for international business and technology brokerage in the life sciences industry, facilitating and negotiating partnership deals among UK, Europe and Global biotech companies with China based large biopharmaceutical, healthcare and MedTech companies. Over the years Marshal Ma as MD of UK Cambridge based technology brokerage company, successfully negotiated many licensed partnership deals between European biotech companies and China biopharmaceutical companies. Since working with Medicilon on strategic alliance and business development project, Marshal combined China licensed partnership deal making with Medicilon CRO services to better serve biotech and pharma companies. Marshal worked on different preclinical projects commissioned by pharma, biotech and leading European CDMOs, coordinated with Medicilon research team to carry out successful PD, PK and safety studies with quality study reports delivered to meet the requirements of FDA, TGA, EMA and NMPA.

hjc黄金城新分子類型聚合賦能平台